ISSN 1662-4009 (online)

ey0018.8-12 | New Concerns | ESPEYB18

8.12. First-Trimester prenatal dexamethasone treatment is associated with alterations in brain structure at adult age

A Van't Westeinde , L Karlsson , A Nordenstrom , N Padilla , S Lajic

J Clin Endocrinol Metab. 2020; 105(8):dgaa340.https://pubmed.ncbi.nlm.nih.gov/32497228/Here, the authors investigated whether prenatal treatment with dexamethasone (DEX) in the first trimester is associated with alterations of brain morphology on MRI scans. Observed MRI alterations were not linked to any alterations in cognitive function or mood, but were associated with DNA methylation in ...

ey0018.8-13 | New Concerns | ESPEYB18

8.13. Perturbed beta-cell function and lipid profile after early prenatal dexamethasone exposure in individuals without CAH

L Wallensteen , L Karlsson , V Messina , A Nordenstrom , S Lajic

J Clin Endocrinol Metab. 2020;105(7): e2439-48.https://pubmed.ncbi.nlm.nih.gov/32433752/Here, the authors investigated the effects of dexamethasone (DEX) on metabolism in individuals without CAH but treated with DEX during the first trimester of fetal life. Prenatal DEX exposure was associated with decreased beta-cell function and higher cholesterol concentrations.Pre...

ey0017.8-6 | Important for Clinical Practice | ESPEYB17

8.6. Cognitive function of children and adolescents with congenital adrenal hyperplasia: Importance of early diagnosis

V Messina , L Karlsson , T Hirvikoski , A Nordenstrom , S Lajic

To read the full abstract: J Clin Endocrinol Metab. 2020; 105(3): dgaa016. PMID: 31927590.Classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency requires life-long glucocorticoid (GC) replacement therapy. Previous studies on general cognitive ability in patients with CAH have been conflicting, and the majority focused on intelligence in adult patients. Some studies h...

ey0015.8-15 | New Concerns | ESPEYB15

8.15 Cognitive impairment in adolescents and adults with congenital adrenal hyperplasia

L Karlsson , A Gezelius , A Nordenström , T Hirvikoski , S Lajic

To read the full abstract: Clin Endocrinol (Oxf). 2017; 87(6): 651-659Patients with CAH are treated with lifelong glucocorticoid (GC) replacement therapy and, for the classic form of the disease, treatment with fludrocortisone is also necessary. During different periods throughout life, it may be difficult to achieve optimal dosing of GC replacement therapy, leading to over- or under-treatment and, t...

ey0017.8-15 | New Concerns | ESPEYB17

8.15. Altered gray matter structure and white matter microstructure in patients with congenital adrenal hyperplasia: Relevance for working memory performance

Westeinde A Van’t , L Karlsson , Sandberg M Thomsen , A Nordenstrom , N Padilla , S Lajic

To read the full abstract: Cereb Cortex. 2020; 30(5): 2777–2788. PMID: 31819952.Congenital adrenal hyperplasia (CAH), most commonly caused by 21-hydroxylase deficiency, is an autosomal recessively inherited life-threatening impairment in cortisol and, in the severe salt wasting form, aldosterone synthesis. The implementation of neonatal screening programs for CAH and the continuous imp...

ey0016.8-15 | New Concerns | ESPEYB16

8.15. Epigenetic alterations associated with early prenatal dexamethasone treatment

L Karlsson , M Barbaro , E Ewing , D Gomez-Cabrero , S Lajic

To read the full abstract: J Endocr Soc. 2018; 3(1): 250–263.Prenatal treatment with dexamethasone (DEX) has been used to avoid virilization in girls with Congenital Adrenal Hyperplasia (CAH). However, it has potential short- and long-term risks and has been associated with cognitive impairments. Here, the authors investigate whether epigenetic modification of DNA during early devel...